Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec 15;7(12):651.
doi: 10.1038/s41408-017-0014-y.

MYD88 mutations predict unfavorable prognosis in Chronic Lymphocytic Leukemia patients with mutated IGHV gene

Shu-Chao Qin  1 , Yi Xia  1 , Yi Miao  1 , Hua-Yuan Zhu  1 , Jia-Zhu Wu  1 , Lei Fan  1 , Jian-Yong Li  2 , Wei Xu  3 , Chun Qiao  4
Affiliations

MYD88 mutations predict unfavorable prognosis in Chronic Lymphocytic Leukemia patients with mutated IGHV gene

Shu-Chao Qin et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interest

The authors declare that they have no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
a Kaplan-Meier estimates of TTT according to MYD88 mutation status among all patients. Time to treatment analysis according to MYD88 mutation status in the CLL patients (N = 284). MYD88 wild-type cases (MYD88 (-)) are represented by the red line. MYD88 mutated cases (MYD88 ( + )) are represented by the blue line. b Kaplan-Meier estimates of OS according to MYD88 mutation status among all patients. Overall survival analysis according to MYD88 mutation status in the CLL patients (N = 284). MYD88 wild-type cases (MYD88 (-)) are represented by the red line. MYD88 mutated cases (MYD88 ( + )) are represented by the blue line. c Kaplan-Meier estimates of TTT according to MYD88 mutation status and IGHV mutation status among M-CLL patients. Time to treatment analysis according to MYD88 mutation status and IGHV mutation status among all CLL patients (N = 284). Of the M-CLL cases, MYD88 wild-type cases (IGHV ( + ) MYD88 (-)) are represented by the red line, while MYD88 mutated cases (IGHV ( + ) MYD88 ( + )) are represented by the blue line. IGHV unmutated cases (IGHV(-)) are represented by the green line. d Kaplan-Meier estimates of OS according to MYD88 mutation status among M-CLL patients. Overall survival analysis according to MYD88 mutation status in the M-CLL patients (N = 165). MYD88 wild-type cases (IGHV ( + ) MYD88 (-)) are represented by the red line. MYD88 mutated cases (IGHV ( + ) MYD88 ( + )) are represented by the blue line
See this image and copyright information in PMC

References

    1. Eichhorst B, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v78–v84. doi: 10.1093/annonc/mdv303. - DOI - PubMed
    1. Ngo VN, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;469:115–9. doi: 10.1038/nature09671. - DOI - PMC - PubMed
    1. Xu L, et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013;121:2051–8. doi: 10.1182/blood-2012-09-454355. - DOI - PMC - PubMed
    1. Varettoni M, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms. Blood. 2013;121:2522–8. doi: 10.1182/blood-2012-09-457101. - DOI - PubMed
    1. Martínez-Trillos A, et al. Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. Blood. 2014;123:3790–6. doi: 10.1182/blood-2013-12-543306. - DOI - PubMed

Publication types

Substances

LinkOut - more resources